Ucb S.a. · EURONEXT:UCB
Ucb — H1 2021 Earnings Presentation
32 slides from Ucb's earnings presentation, Jul 29, 2021
Slide 1: Delivering on Our Strategy and Guidance
First Half 2021 Delivering on Our Strategy and Guidance 29 July 2021 Analysts’ and Investors’ Call
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor 2021 HY - 2 Forward-looking statements This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and simila
Slide 3: 2021 HY Report
2021 HY Report 2021 HY - 3 Jean-Christophe Tellier OUR PURPOSE CEO Create Value for Patients, Now and Into the Future Emmanuel Caeymaex BIMZELX® Executive Vice President Ready for launch Immunology Solutions & Head of U.S. Iris Loew-Friedrich CLINICAL PIPELINE ON TRACK CMO Six Phase 3 Study Read Out
Slide 4: Our Purpose – Create Value for Patients, Now and Into the Future
2021 HY - 4 Our Purpose – Create Value for Patients, Now and Into the Future Jean-Christophe Tellier CEO
Slide 5: UCB on Track
2021 HY - 5 Sustained Growth UCB on Track Sustainable UCB on Track Growth Resilience
Slide 6: 2021 HY Results | At-a-Glance
2021 HY Results | At-a-Glance 2021 HY - 6 Sustainable growth, with recent NAYZILAM® and EVENITY® launches, and the upcoming launch of BIMZELX® and beyond Net Sales € 2.8 Billion Revenue € 2 651 Million +11% CER (+7%) (+6%) Underlying Profitability (adj. EBITDA) € 843 Million or 30% of Revenue (+8%;
Slide 7: COVID Pandemic Update
2021 HY - 7 COVID Pandemic Update Market Dynamics Supply Clinical Pipeline Improvement in patient No material impact on Unfolding as anticipated demand (volume) visible distribution and supply We are actively managing With regional differences: We are actively managing the challenges U.S. the challe
Slide 8: Integrating Sustainability
2021 HY - 8 Integrating Sustainability Our Business Approach
Slide 9: We Aim to Lead in Specific Patient Populations by 2025
We Aim to Lead in 5 Specific Patient Populations by 2025 2021 HY - 9 Creating value for patients Partial Onset / Focal Epileptic Seizures KEPPRA®, VIMPAT®, BRIVIACT®, NAYZILAM®, STACCATO® alprazolam* Psoriatic Arthritis CIMZIA®, bimekizumab* Woman of Childbearing Age CIMZIA® & KEPPRA®** Osteoporosis
Slide 10: BIMZELX ...Ready for Launch
2021 HY - 10 BIMZELX ® ...Ready for Launch Emmanuel Caeymaex Executive Vice President Immunology Solutions & Head of U.S.
Slide 11: CIMZIA Reaches More Patients Thanks to Differentiation
CIMZIA® Reaches More Patients Thanks to Differentiation 2021 HY - 11 Presence in the market and learnings to support BIMZELX® launch 2021 HY Net Sales Europe € 873 Million 15% 12.2% 13.7% 12.8% (+4%; +11% CER) EU 10% 24% 5% (-1%) U.S. Rheumatology 0% PFS anti-TNF Biologics CIMZIA 36% Market Share In
Slide 12: BIMZELX (bimekizumab)
BIMZELX® (bimekizumab) The safety and efficacy of bimekizumab have not been established and it is not approved by any regulatory authority worldwide.
Slide 13: The $19 billion psoriasis market is growing and dynamic
2021 HY - 13 The $19 billion psoriasis market is growing and dynamic 1 A majority of biologics/new orals psoriasis patients are new 7% of patients start or change to a drug within one-two years3 drug every month 2 100% % Continuing 90% from M1 Continuing YEAR 2 80% 92.9% 70% Switch % Patients 60% YE
Slide 14: Bimekizumab has the potential to raise treatment expectations
2021 HY - 14 Bimekizumab has the potential to raise treatment expectations In Phase-III clinical studies, bimekizumab demonstrated: Patients with moderate-to-severe Magnitude of response plaque psoriasis place a high value on ~6 out of 10 patients achieved PASI 100 at Week 16 2,3,4 treatment which p
Slide 15: Network meta-analysis: bimekizumab highest ranked in efficacy
2021 HY - 15 In a network meta-analysis bimekizumab was the highest ranked treatment in terms of efficacy - PASI 100 and PASI 90 (10-16 weeks) 1 The probability of bimekizumab being better than every other comparator was ≥99.9% for PASI 100 and PASI 901 Anti-IL Anti-TNF Non-Biologics 0% 10% 20% 30%
Slide 16: Strong foundations for an exceptional experience at launch
2021 HY - 16 Strong foundations for an exceptional experience at launch PATIENTS The safety and efficacy of bimekizumab have not been established and it is not approved by any regulatory authority worldwide.
Slide 17: Clinical Pipeline: On Track – Six Phase 3 Study Read Outs Ahead
2021 HY - 17 Clinical Pipeline On Track – Six Phase 3 Study Read Outs Ahead Iris Loew-Friedrich CMO
Slide 18: UCB's Late-Stage Pipeline | All Timelines Confirmed
UCB’s Late-Stage Pipeline | All Timelines Confirmed 2021 HY - 18 Positive CHMP Opinion Read Out Earlier than Expected New Indication New Indication Phase 2 Started Phase 2a Started *EU: CHMP positive opinion June 2021, U.S. PDUFA date 15 Oct 2021. ** in partnership with Biogen. *** in partnership wi
Slide 19: 2021 HY Financials – Solid Performance Enabling Future Growth
2021 HY - 19 2021 HY Financials – Solid Performance Enabling Future Growth and Investment in Innovation Sandrine Dufour CFO
Slide 20: Strong Underlying Net Sales Growth
Strong Underlying Net Sales Growth 2021 HY - 20 Resilient product portfolio, change of E KEPPRA® distribution model & new launches 2021 HY Net Sales Act CER € 2 651 Million (+6%; +11% CER) CIMZIA® € 873 M +4% +11% Driven by new patient populations VIMPAT ® € 735 M +2% +9% Strong growth at CER in all
Slide 21: 2021 HY Financial Highlights
2021 HY Financial Highlights 2021 HY - 21 Very solid growth from top- to bottom line 2021 Actual CER Revenue Net Sales € 2 651 Million +6% (+11% CER) € 2 778 million +7% +11% Driven by volume growth and change of E KEPPRA® distribution model in Japan Gross Profit Gross margin improved from 74% to 75
Slide 22: Financial Guidance 2021 Confirmed
Financial Guidance 2021 Confirmed 2021 HY - 22 UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential challenges Revenue € 5.45 - 5.65 Peak Sales Continued strong core Billion products growth, tracking towards confirmed peak sales Adjusted EBITDA* / 27 - 28% Re
Slide 23: 2025 | How We Get There… Topline Evolution
2025 | How We Get There… Topline Evolution 2020 FY - 23 BRIVIACT® 2025 NAYZILAM® Leadership in EVENITY® 5 patient populations > € 6 billion NEUPRO®, VIMPAT® and revenue CIMZIA® patent expiration 2020 BIMZELX® in STRONG 5 indications* PRODUCT rozanolixizumab and PORTFOLIO zilucoplan launches * Psoria
Slide 24: 2025 | How We Get There… Building Blocks Margin
2025 | How We Get There… Building Blocks Margin 2020 FY - 24 Gross Improving thanks to product mix Margin Operating M&S and R&D decreasing as a % of revenues Leverage Low- to mid-thirties % EBITDA margin EVENITY® Higher share of contribution vs share of revenues Margin
Slide 25: What the Future Holds…
2021 HY - 25 What the Future Holds… Jean-Christophe Tellier CEO
Slide 26: …Supported by UCB's Late-Stage Pipeline
…Supported by UCB’s Late-Stage Pipeline 2021 HY - 26 All timelines confirmed *EU: CHMP positive opinion June 2021, U.S. PDUFA date 15 Oct 2021 ** in partnership with Biogen *** in partnership with Roche/Genentech Zilucoplan in amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial MOG - my
Slide 27: Sustainability as an Approach for Business Growth and Societal Impact
We See Sustainability as an Approach for Business 2021 HY - 27 Growth and Societal Impact 2022-2025 Value for people Value for Value for patients at UCB and our Value the planet shareholders communities We aim to bring to We are creating the By 2030, we will be By 2025, we will lead patients right c
Slide 28: Continuing to Advance on Our Sustainable Growth Journey
…Continuing to Advance on Our Sustainable Growth Journey 2021 HY - 28 Value for people at UCB Value for Value for patients Value the planet and our communities shareholders Long Term Progressing on our Hybrid working model -23.7% vs. -3%* Objectives Access Performance announced as year end target fo
Slide 29: Leadership in Specific Patient Populations by 2025
Leadership in 5 Specific Patient Populations by 2025… 2021 HY - 29 Creating value for patients Partial Onset / Focal Epileptic Seizures KEPPRA®, VIMPAT®, BRIVIACT®, NAYZILAM®, STACCATO® alprazolam* Psoriatic Arthritis CIMZIA®, bimekizumab* Woman of Childbearing Age CIMZIA® & KEPPRA®** Osteoporosis-R
Slide 30: Guidance 2025
2021 HY - 30 Guidance 2025 Leading in 5 specific patient populations Financial guidance – at least € 6 billion top line, low- to mid-thirties EBITDA margin Improved ESG rating performance
Slide 31: UCB on Track
2021 HY - 31 Sustained Growth UCB on Track Sustainable UCB on Track Growth Resilience
Slide 32: Inspired by patients. Driven by science.
~ bd nspired by patients. Driven by science.